About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Refractory Diffuse Large B-cell Lymphoma

NCT03664336·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Hospices Civils de Lyon

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

≥18 years of age
diagnosed with DLBCL at Lyon Sud University Hospital (LSUH) from January 2002 to January 2017
presented with refractory disease in response to front-line therapies
including anthracycline-based chemo and a monoclonal anti-CD20 antibody

You may not be if

Patients with a history of indolent lymphoma,
Patients with a primary central nervous system (CNS) lymphoma or immunosuppression-related lymphoma

The record

StatusCompleted

PhaseNo phase

Taking part104

StartedNov 2016

UpdatedSep 10, 2018

Conditions

Diffuse Large B-cell Lymphoma

Where1

Centre Hospitalier Lyon Sud
Pierre-Bénite, France

Clareo Health | Refractory Diffuse Large B-cell Lymphoma